CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
IPO Year:
Exchange: AMEX
Website: cormedix.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/30/2025 | Buy → Hold | D. Boral Capital | |
| 6/30/2025 | $20.00 | Buy | H.C. Wainwright |
| 3/7/2025 | $18.00 | Outperform | Leerink Partners |
| 1/13/2025 | $15.00 | Buy | D. Boral Capital |
| 8/26/2024 | $13.00 | Buy | Rodman & Renshaw |
| 8/10/2023 | $6.00 | Outperform | RBC Capital Mkts |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
3 - CorMedix Inc. (0001410098) (Reporting)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4/A - CorMedix Inc. (0001410098) (Issuer)
4/A - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
4 - CorMedix Inc. (0001410098) (Issuer)
144 - CorMedix Inc. (0001410098) (Subject)
144 - CorMedix Inc. (0001410098) (Subject)
144 - CorMedix Inc. (0001410098) (Subject)
8-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
10-Q - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
8-K - CorMedix Inc. (0001410098) (Filer)
424B5 - CorMedix Inc. (0001410098) (Filer)
424B5 - CorMedix Inc. (0001410098) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
D. Boral Capital downgraded Cormedix from Buy to Hold
H.C. Wainwright initiated coverage of Cormedix with a rating of Buy and set a new price target of $20.00
Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00
D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00
RBC Capital Mkts initiated coverage of Cormedix with a rating of Outperform and set a new price target of $6.00
Needham reiterated coverage of Cormedix with a rating of Buy and set a new price target of $29.00 from $31.00 previously
Needham initiated coverage of Cormedix with a rating of Buy and set a new price target of $31.00
Truist Securities reiterated coverage of Cormedix with a rating of Buy and set a new price target of $35.00 from $20.00 previously
Fastest customizable press release news feed in the world
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif., Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the develo
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (NASDAQ:TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing. Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad™ and for pre-launch preparations. Talphera is a specialty pharm
- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential - - Revised guidance of pro forma 2025 combined revenues, now estimated to be in the range of $325 to $350 million - - Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million - BERKELEY HEIGHTS, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for
BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September. Cantor Global Healthcare Conference Date:September 5, 2025Time:8:35am EasternFormat:Fireside ChatWebcast:Link to webcast Morgan Stanley 23rd Annual Global Healthcare Conference Date:September 10, 2025Time:10:45am EasternFormat:Fireside ChatWebcast:Link to webcast About CorMedix CorMedix In
CorMedix to pay Melinta $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders The agreement also includes a regulatory milestone payment of up to $25 million and royalties Transformational deal that strengthens and diversifies commercial product portfolio for CorMedix Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announces that it has entered into a definitive agreement to be acquired by CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therap
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD) today announced financial results for the second quarter and six months ended June 30, 2025 and provided an update on its business announcing the acquisition of Melinta Therapeutics LLC, with a target closing date as early as September 1, 2025. Second Quarter and Six Months 2025 Financial Highlights For the second quarter of 2025, CorMedix recorded $39.7 million in net revenue from sales of De
Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potentialTransaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionPro forma 2025 combined revenues estimated to be $305 to $335 millionAdvances CorMedix's strategy to build a formidable specialty pharmaceutical business through a combination of organic and inorganic growthDynamic platform can be leveraged to support additional products and expand as the combined company enters its next ph
BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The closing of the offering is expected to occur on or about June 30, 2025, subject to
BERKELEY HEIGHTS, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it intends to offer and sell $85.0 million of shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by CorMedix. In addition, CorMedix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, at the public offering price, less underwriting discounts and commissions. The offering is subje
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025. CorMedix's LDO customer has commenced ordering and will begin the implementation of DefenCath in its patients. Implementation will initially target at least 50% more patients than previously communicated, with the opportunity for further expansion. In connection with this expanded utilization, CorMedix has amended its existing agr
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation
Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination
Live Leadership Updates
BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has
– CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea
BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval
BERKELEY HEIGHTS, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Joseph Todisco as Chief Executive Officer of the company. Mr. Todisco also will join the CorMedix Board of Directors. The company expects Mr. Todisco to join CorMedix on May 16th or such earlier date as he completes his contractual responsibilities to his current employer. Myron Kaplan, Chairman of CorMedix's Board of Directors commented, "We are delighted to welcome Joe to CorMedix as the new Chief Executi
BERKELEY HEIGHTS, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the first quarter ended March 31, 2021 and provided an update on recent business events. Recent Business Highlights: CorMedix announced the appointment of Tom Nusbickel as the Company's Executive Vice President and Chief Commercial Officer.CorMedix successfully completed the agreed upon protocol for the manual extraction study identified in the Complete Response Letter that FDA is requiring as confirmatio
Live finance-specific insights
‒ Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm ‒ ‒ Company Announces Acquisition of Melinta Therapeutics ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD) today announced financial results for the second quarter and six months ended June 30, 2025 and provided an update on its business announcing the acquisition of Melinta Therapeutics LLC, with a target closing date as early as September 1, 2025. Second Quarter and Six Months 2025 Financial Highlights For the second quarter of 2025, CorMedix recorded $39.7 million in net revenue from sales of De
Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potentialTransaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionPro forma 2025 combined revenues estimated to be $305 to $335 millionAdvances CorMedix's strategy to build a formidable specialty pharmaceutical business through a combination of organic and inorganic growthDynamic platform can be leveraged to support additional products and expand as the combined company enters its next ph
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in
BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am ETDomestic: 1-844-481-2557International: 1-412-317-0561Conference ID: 10197392Webcast: Webcast Link About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and comme
‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its first full quarter of DefenCath sales since commencing outpatient launch in July 2024. The Com
BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2024, before the market opens on Wednesday, October 30, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, October 30th @ 8:30am EDTDomestic:1-844-481-2557International:1-412-317-0561Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the second quarter and six months ended June 30, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports our initial partial quarter of sales since DefenCath's inpatient launch on April 15th. The Company reported net sales of $0.8 million for the second quarter, which primarily represents trade stocking for inpatient facilities. The company has started to see pull-through of units to inpati
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Wednesday, August 14, 2024, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, August 14th @ 8:30am ET Domestic:1-877-270-2148International:1-412-902-6510Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the pr
This live feed shows all institutional transactions in real time.
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G/A - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13G - CorMedix Inc. (0001410098) (Subject)
SC 13D/A - CorMedix Inc. (0001410098) (Subject)